A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's disease.

Trial Profile

A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C for 4 weeks, using donepezil as calibrator, in patients with mild Alzheimer's disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs SSR 180711 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 03 May 2012 Additional locations (Italy, Spain, Sweden) added as reported by European Clinical Trials Database record.
    • 22 Jul 2009 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Planned end date changed from 1 Sep 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top